- Home Page
- What's New?
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Clinical Trials
- Resources
- Contact Us
Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Clinical Trials
- Cancer Biomarkers
- Multiple Myeloma
- Receptor-Mediated Endocytosis
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Multiple Myeloma
- Future Directions
- Antibody-Drug conjugates
- HER Signaling
- Receptor-Mediated Endocytosis
- Anti-PDL1 (MPDL3280A)
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Apoptosis
- MAPK Signaling
- PI3K/Akt/mTOR Signaling
- MEK Inhibitor (GDC-0973)
- PI3K Inhibitor (GDC-0941)
- Glossary
- Resisting apoptosis
- Emerging therapeutic options
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Slide decks and videos
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Melanoma
- Multiple Myeloma
- Traditional Monoclonal Antibodies
- Angiogenic Signaling
- HER Signaling
- Anti-PDL1 (MPDL3280A)
- Emerging therapeutic options
- Inhibition of HER2 dimerization
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Glossary
- Slide decks and videos
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Melanoma
- Antibody-Drug conjugates
Oncogenic BRAF is expressed in a variety of melanoma subtypes
Historically, the classification of primary melanoma has been determined by site of origin, tumor thickness, and histological subtype. For instance, cutaneous melanoma, a primary site of melanoma, has been subclassified into 4 groups with distinct clinicopathologic features: superficial spreading, nodular, lentigo maligna, and acral lentiginous melanoma (Figure 2).17
Ongoing genetic studies using a variety of technologies, including DNA sequencing and immunohistochemistry, are demonstrating specific genotype-phenotype correlations that provide insights into molecular subclassifications of melanoma and the heterogeneous nature of this malignancy.17
Continuing research into determining whether molecular pathways of tumor progression differ between subtypes of cutaneous melanoma is critical in order to ensure the most appropriate treatments can be offered to the right patient subtype.24
Superficial spreading malignant melanomas and lentigo maligna melanomas
A study by Saldanha et al concluded that while the mutational frequency of BRAF differed between cutaneous melanoma subtypes, BRAF mutations were most frequent in superficial spreading malignant melanomas and lentigo maligna melanomas. Superficial spreading melanoma is commonly associated with sun exposure and comprises 70% of primary cutaneous melanomas. Lentigo maligna melanomas are diagnosed as thin lesions and commonly manifest on the faces of older individuals. Identification of BRAF mutations in these patients suggests that the activation of the RAS-RAF pathway may be an important genetic feature of these melanomas.15,25
Figure 2
- A.
-
Reprinted with permission from MacMillan Publishers Ltd: Mod Pathol, 2006.
- B.
-
Reprinted with permission from MacMillan Publishers Ltd: Mod Pathol, 2006.
A) Histology of superficial spreading melanoma comprises haphazardly distributed atypical melanocytes present as single cells and/or nests of cells throughout different levels of the epidermis. B) Histology of lentigo maligna. The tumor is typically characterized by confluent single melanocytes aligned along the dermal-epidermal junction and spreading down cutaneous appendages. The cells are small and do not normally exhibit hyperchromatic nuclei and pagetoid extensions. An underlying solar elastosis is common in this subcategory of tumors.26,27